Evidence map›Paper›PMID 34476573›Full record

ArticleAnnals of hematology2021

The anemia-independent impact of myelodysplastic syndromes on health-related quality of life.

Hanneke J C M Wouters, Annette Conrads-Frank, Karin A Koinig, Alex Smith, Ge Yu, Theo de Witte, Bruce H R Wolffenbuttel, Gerwin Huls, Uwe Siebert, Reinhard Stauder and 2 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Annals of hematology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 16 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 4 countries.

Hanneke J C M WoutersDepartment of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands. h.j.c.m.wouters@umcg.nl.
Annette Conrads-FrankInstitute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.
Karin A KoinigDepartment of Internal Medicine V (Hematology and Oncology), Medical University Innsbruck, Innsbruck, Austria.
Alex SmithEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
Ge YuEpidemiology and Cancer Statistics Group, Department of Health Sciences, University of York, York, UK.
Theo de WitteDepartment of Tumor Immunology, Radboud University Medical Center, Nijmegen, The Netherlands.
Bruce H R WolffenbuttelDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, 9700 RB, Groningen, The Netherlands.
Gerwin HulsDepartment of Hematology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Uwe SiebertInstitute of Public Health, Medical Decision Making and Health Technology Assessment, Department of Public Health, Health Services Research and Health Technology Assessment, UMIT - University for Health Sciences, Medical Informatics and Technology, Hall in Tirol, Austria.
Reinhard StauderDepartment of Internal Medicine V (Hematology and Oncology), Medical University Innsbruck, Innsbruck, Austria.
Melanie M van der KlauwDepartment of Endocrinology, University of Groningen, University Medical Center Groningen, 9700 RB, Groningen, The Netherlands.
MDS-RIGHT partners
Innsbruck Medical University · ATUniversity Medical Center Groningen · NLUniversity of Groningen · NLUniversity of York · GBMassachusetts General Hospital · USRadboud University Medical Center · NL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myelodysplastic syndromes (MDS) are in the majority of cases characterized by anemia. Both anemia and MDS per se may directly contribute to impairments in health-related quality of life (HRQoL). In this study, we aimed to investigate the anemia-independent impact of MDS on HRQoL. We evaluated participants (≥ 50 years) from the large population-based Lifelines cohort (N = 44,694, mean age 59.0 ± 7.4 years, 43.6% male) and the European MDS Registry (EUMDS) (N = 1538, mean age 73.4 ± 9.0 years, 63.0% male), which comprises a cohort of lower-risk MDS patients. To enable comparison concerning HRQoL, SF-36 scores measured in Lifelines were converted to EQ-5D-3L index (range 0-1) and dimension scores. Lower-risk MDS patients had significantly lower HRQoL than those from the Lifelines cohort, as illustrated in both the index score and in the five different dimensions. Multivariable linear regression analysis demonstrated that MDS had an adjusted total impact on the EQ-5D index score (B =  - 0.12, p < 0.001) and an anemia-independent "direct" impact (B =  - 0.10, p < 0.001). Multivariable logistic regression analysis revealed an anemia-independent impact of MDS in the dimension mobility, self-care, usual activities, and anxiety/depression (all except pain/discomfort). This study demonstrates that the major part of the negative impact of lower-risk MDS on HRQoL is not mediated via anemia. Thus, the therapeutic focus should include treatment strategies directed at underlying pathogenic mechanisms to improve HRQoL, rather than aiming predominantly at increasing hemoglobin levels.

Indexed as

Quality of LifeAgedAged, 80 and overAnemiaFemaleHumansLongitudinal StudiesMaleMiddle AgedMyelodysplastic SyndromesAnemiaHealth-related quality of lifeHemoglobinMyelodysplastic syndromes

Identifiers

PMID34476573
PMCPMC8592948
OpenAlexW3196431630

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.